

Curriculum Vitae

PERSONAL DATA

Name: Sancy A. Leachman
(b) (6)

EDUCATION

<u>Years</u>	<u>Degree</u>	<u>Institution (Area of Study)</u>
1982 - 1985	B.A.	University of Texas at Austin Plan II (Liberal Arts) Austin, TX
1985 - 1993	M.D., Ph.D.	University of Texas Dallas, TX
1993 - 1994	Intern	University of Texas Southwestern Medical School (Internal Medicine) Dallas, TX
1994 - 1997	Resident	Yale - New Haven Hospital (Dermatology) New Haven, CT
1997 - 1998	Fellow	Yale University School of Medicine (Cutaneous Oncology) New Haven, CT

BOARD CERTIFICATIONS

09/29/1997 American Board of Dermatology, Certified

CURRENT LICENSES/CERTIFICATIONS

1999 - 2010 State License (UT) - Physician (MD)
1999 - 2010 Controlled Substance (UT) - Physician (MD)
2006 - 2012 DEA Certificate (UT) - Physician (MD)

ACADEMIC HISTORY

Dermatology

09/01/1998 Hire, Tenure Track, Assistant Professor
07/01/2006 Tenure
07/01/2006 Promotion, Associate Professor

PROFESSIONAL EXPERIENCE

Full Time Positions

1998 - 2000 Fellow-to-Faculty Transition Program through Molecular Genetics (Medical Institute Funded),
University of Utah, Department of Dermatology, Salt Lake City, UT
1998 - 2006 Assistant Professor, University of Utah, Department of Dermatology, Salt Lake City, UT
2000 - Present Member, Investigator and Director of the Tom C. Mathews Familial Melanoma Research Clinic,
Huntsman Cancer Institute, Salt Lake City, UT
2000 - Present Investigator, Director, Huntsman Cancer Institute, Familial Melanoma Research Clinic, Salt Lake
City, UT
2003 - 2007 Co-leader, Huntsman Cancer Institute, Salt Lake City, UT
2006 - Present Associate Professor, University of Utah, Department of Dermatology, Salt Lake City, UT
2007 - Present Director, Huntsman Cancer Institute, Melanoma & Cutaneous Oncology Program, Salt Lake City, UT

Part Time Positions

1997 - 1998 Clinical Dermatologist, Michael Friedman & Associates, Stanford, CT
1997 - 1998 Clinical Dermatologist, Yale Health Plan, New Haven, CT

Editorial Experience

2000 - Present Editor for Melanoma Program Newsletter
2005 - Present Editorial Board for Reviewer, Archives of Dermatology
2005 Co-editor for Symposium Proceedings, Journal of Investigative Dermatology
2010 - Present Editor for Journal of Investigative Dermatology, Pachyonychia Congenita Special Volume

Reviewer Experience

Reviewer Annals of Internal Medicine
Reviewer for American Academy of Dermatology, Derm Clips
Reviewer for Journal of Cutaneous Pathology
Reviewer for Journal of Investigative Dermatology
Reviewer for Journal of Virology
Reviewer Journal of Medical Genetics
Reviewer Journal of the American Academy of Dermatology
Reviewer Obstetrics & Gynecology

SCHOLASTIC HONORS

1981 M.D. Anderson Cancer Center Summer Research Fellow
1982 - 1985 Plan II Honors Program
1983 Texas Heart Institute, Denton Cooley Associates Surgical Fellowship
1983 - 1985 Junior Fellows Research Honor Society, U.T., Austin
1985 - 1986 Southwestern Medical Foundation Scholarship
1985 - 1993 NIH, Medical Scientist Training Program, Grant Recipient
1990 Scholarship, Kinase Symposium, La Londe, France, North Atlantic Treaty Organization and Federation of European Biochemical Societies
1996 - 1998 NIH Training Fellowship, Yale University, Department of Dermatology
2002 Ladies Home Journal, Health Hero
2005 "Advocate of the Year", State of Utah Department of Health and the Cancer Crusaders Organization

ADMINISTRATIVE EXPERIENCE

Administrative Duties

Professional Organization & Scientific Activities

1987 - 1989 Member, American Heart Association, Ad Hoc Grant Review Committee
2000 - 2002 Member, Dermatology Foundation, Medical & Scientific Committee Advisory Board
2003 - 2006 Member, American Academy of Dermatology, Melanoma/Skin Cancer Committee
2003 Member, Society for Investigative Dermatology, Committee on Education
2004 - Present Member, Southwest Oncology Group, Chemoprevention Working Group
2004 - 2008 Chair, International Pachyonychia Congenita Consortium
2005 - Present Member, Foundation for Ichthyosis & Related Skin Types, Medical & Scientific Committee
2005 - 2006 Co-Chairperson, Society for Investigative Dermatology, Abstract Selection Committee
2006 - Present Member, Society for Investigative Dermatology, Translational Task Group
2006 - Present Board Member, Pan American Society for Pigment Cell Research
2009 - 2010 Chair, Society for Investigative Dermatology, Committee on Education

Grant Review Committee/Study Section

1987 - 1989 Ad Hoc Grant Review/Triage Committee, American Heart Association
1997 - 1998 Ad Hoc Grant Reviewer, Yale National Center of Excellence in Women's Health
2004 Ad Hoc Reviewer, Veterans Administration Merit Review Grant Program
2004 Ad Hoc Reviewer, Young Investigator Award, Whitehead Institute

2006 - Present Ad Hoc NIH R03, PPG and SPORE Grant Reviewer

Symposium/Meeting Chair/Coordinator

2001 Cowan Symposium Committee - Co-Director

2005 "Melanoma Therapeutics" Symposium, Nineteenth International Pigment Cell Conference, Reston, Virginia - Invited Co-Director

2005 "Melanoma and Pigmented Lesions" Symposium, Society for Investigative Dermatology, St. Louis, Missouri - Invited Co-Director

2007 - Present Pan American Society for Pigment Cell Research - Director of Session

2007 - Present First Global Workshop on Malignant Melanoma - Epidemiology Session Leader

PROFESSIONAL COMMUNITY ACTIVITIES

1997 - 1998 Committee Member, Yale School of Medicine, Yale National Center of Excellence in Women's Health, Ad Hoc Grant Reviewer

2000 - 2001 Board Member, SuperGen Inc., Clinical Advisory Board Member

2002 - 2004 Co-Chair, Cancer Wellness House, Melanoma/Skin Cancer Awareness Network

2003 - Present Local Principal Investigator, GenoMEL, International Melanoma Consortium

2003 - Present Medical Director & Chairperson, Pachyonychia Congenita Project, Medical & Scientific Advisory Board

2004 - Present Chair, Pachyonychia Congenita Project, Medical & Scientific Advisory Board

2005 - Present Member, Melanoma Care Coalition

2005 - Present Member, Southwest Oncology Group, Chemoprevention Working Group

2005 - 2008 Medical Advisor, Utah Department of Health, Genetics Committee

2007 - Present Co-Organizer, Aim at Melanoma Foundation

2008 - Present Member, Aim at Melanoma Foundation, International Melanoma Working Group (IMWG)

2010 - Present Organizer & Host, Pan American Society for Pigment Cell Research, Annual meeting in Salt City

UNIVERSITY COMMUNITY ACTIVITIES

University Level

2007 - Present Member, Utah Population Database, Development Committee

Health Sciences Level

1999 - 2000 Faculty Member, Microarray Core Facility, Administration of Users Meeting

College Level

1999 - Present Faculty Mentor, Medical Student Research Program

2002 - Present Participant, Day with a Doctor, Program for Medical Students

2006 Faculty Advisor, School of Medicine, Sun Smart Program

Department Level

1996 - 1997 Coordinator, Dermatology, Yale Dermatology Residents Journal Club

1998 - 2009 Committee Member, Dermatology, Department of Dermatology Research in Progress

1998 - 2008 Member, Dermatology, Resident Selection Committee, Residency Applicants Sub-Committee

Programs, Centers & Institutes

1998 - Present Volunteer, Huntsman Cancer Institute, Skin Cancer Screening Clinics, Community Skin Screenings

2000 - 2007 Supervisor, Melanoma Cutaneous Oncology Program, Clinical Database Development Team (CCR)

2000 - Present Director, Melanoma Cutaneous Oncology Program, Management of the Familial Melanoma Research Clinic, including Clinic Coordinator and Genetic Counselor

2000 - 2002 Director, Melanoma Cutaneous Oncology Program, Scientific Journal Club

2000 - 2002 Director, Melanoma Cutaneous Oncology Program, Joint Laboratory Meetings

2000 - Present Director, Melanoma Cutaneous Oncology Program, Website Development Team

2003 - 2006 Member, Eccles Institute of Human Genetics, Advisory Committee

2004 - Present Member, Huntsman Cancer Institute, Cancer Center Support Grant Meeting

2004 - 2007 Member, Huntsman Cancer Institute, Translational Research Committee

2008 - Present Director, Melanoma Cutaneous Oncology Program

SERVICE AT AFFILIATED INSTITUTIONS

2002 - Present Attending Physician, Primary Children's Medical Center
2002 - Present Attending Physician, Salt Lake Veterans Administration Medical Center

SERVICE AT PREVIOUS INSTITUTIONS

CURRENT MEMBERSHIPS IN PROFESSIONAL SOCIETIES

American Medical Association
American Academy of Dermatology
Society for Investigative Dermatology
Intermountain Dermatology Society
National Vitiligo Foundation
Utah Medical Association
Vitiligo Society
American Association for Cancer Research
American Society of Human Genetics
Pan American Society for Pigment Cell Research
Utah Society of Dermatologic Medicine and Surgery
Medical Dermatology Society
Southwest Oncology Group

FUNDING

Active Grants

07/01/01 - Present Familial Melanoma Research (endowment)
Tom C. Mathews Jr. Foundation
Huntsman Cancer Institute
Role: Principal Investigator

12/01/05 - 11/30/10 Genetic And Environmental Determinants Of Melanoma: Trans
Principal Investigator: Lisa A. Cannon-Albright
Direct Costs: \$205,320 Total Costs: \$246,384
European Commission
Role: Principal Investigator

09/03/06 - 09/29/10 Lovastatin Melanoma Pathobiology
Principal Investigator: Wolfram E. Samlowski
Direct Costs: \$264,773 Total Costs: \$363,067
University of California Irvine
Role: Principal Investigator


09/20/08 - 09/19/10 Pc Ind Study
Direct Costs: \$136,667 Total Costs: \$176,235
NIH National Center for Research Resources (NCRR)
Role: Principal Investigator

06/01/09 - 05/31/11 Sulforaphane And Melanoma
Direct Costs: \$ (b) (4) Total Costs: \$ (b) (4)
Melanoma Research Foundation
Role: Principal Investigator

06/01/09 - 05/31/11 (b) (4)

- 07/01/09 - 06/30/14 Impacts Of MC1R Functional Variants on the DNA Damage Response of Human Melanocytes
 Direct Costs: \$50,306 Total Costs: \$75,711
 Sub Contract with Univ. of Cincinnati / National Institutes of Health (NIH)
 Role: Co-Principal Investigator
- 07/01/10 - 06/30/12 Molecular Determinants of Melanoma
 US Department of Defense
 Role: Co-Principal Investigator
- 07/01/10 - 06/30/11 The SCOPE Project: Skin Cancer Outdoor Prevention Education
 Principal Investigator: Jeffrey Paul Yancey
 Utah Cancer Action Network
 Role: Co-Investigator

Pending Grants

05/20/10 - 05/20/13  (b) (4)

12/01/10 - 11/30/15 Sulforaphane And Melanoma
 Principal Investigator: Philip J. Moos
 NIH National Cancer Institute (NCI)
 Role: Co-Investigator

04/01/11 - 03/31/16 Impact On Melanoma Testing
 National Institutes of Health
 Role: Principal Investigator

Past Grants

09/01/98 - 07/01/01 Fellow-to-Faculty Transition Program
 Howard Hughes Medical Institute
 Role: Trainee

07/01/99 - 06/30/00 Systematic Identification Of Genes Regulating Papillomavirus-Induced Transformation. Funding Incentive Seed Grant Program.
 Direct Costs: \$34,000 Total Costs: \$34,000
 University of Utah Research Foundation
 Role: Principal Investigator

07/01/99 - 04/24/00 Systematic Identification Of Genes Regulating Papilloma Virus Induced Transformation. Cost Reimbursable.
 Direct Costs: \$  Total Costs: \$ 
 Dermatology Foundation
 Role: Principal Investigator

04/01/00 - 11/01/02  (b) (4)

07/01/00 - 06/30/04 Familial Melanoma
 Doris Duke Charitable Foundation (DDCF)
 Role: Principal Investigator

07/01/00 - 06/30/03 Identification Of Molecular Pathways Regulating Papillomavirus-Induced Transformation. Cost Reimbursable. Closed 11-6-00.
 Direct Costs: \$  Total Costs: \$ 
 Dermatology Foundation
 Role: Principal Investigator

01/01/02 - 12/01/04 Post-translational Modifications of DNA Damage Response Proteins as a Measure of Cellular Response to Low Doses of Ionizing RD
 US Department of Energy
 Role: Collaborator

09/01/03 - 08/01/08 Identification of Melanoma Loci (Research type R01)
National Institutes of Health (NIH)
Role: Co-Investigator

07/01/04 - 06/30/05 Elucidation Of The Role Of The Melanocortin 1 Receptor Gene As A Melanoma Susceptibility Gene. Cost Reimbursable.
Direct Costs: \$ (b) (4) Total Costs: \$ (b) (4)
Dermatology Foundation
Role: Principal Investigator

06/01/05 - 05/01/06 A Prospective Longitudinal Study of Psychological and Behavior Responses to the Receipt of *p16* Genetic Testing Results
University of Utah
Role: Co-Principal Investigator

06/01/05 - 06/01/06 Behavioral Aspects of Melanoma Patients Undergoing Care (Research type K07)
National Institutes of Health
Role: Collaborator

07/01/05 - 06/30/06 Detection And Characterization Of Premalignant Transformation Of Melanoma. Technol Commerc
Prog. Cost Reimbursable.
Direct Costs: \$ (b) (4) Total Costs: \$ (b) (4)
Dermatology Foundation
Role: Principal Investigator

12/29/05 - 09/30/06 (b) (4)

09/01/06 - 08/01/08 A New Method for Delivery of selenium for Prevention of Melanoma (Research type R03)
National Institutes of Health (NIH)
Role: Collaborator

09/01/06 - 08/01/08 Oxidative Stress and Melanoma Chemoprevention (Research type RO3)
National Institutes of Health (NIH)
Role: Collaborator

Active Contracts

Pending Contracts

Past Contracts

TEACHING RESPONSIBILITIES/ASSIGNMENTS

Course and Curriculum Development

Courses Directed

Course Lectures

Clinical Teaching

2000 - Present Attending in Resident Clinic, rotating schedule, 2-4 residents

Laboratory Teaching

Small Group Teaching

1999 - 2008 Monthly dermatology lecture, 1-5 medical students or residents
2000 - 2006 Journal clubs, rotating schedule, 1-5 fellows
2001 - 2004 Molecular Biology of Cancer, Cell Cycle Regulation lectures (2), 25-40 students
2010 - Present Annual Didactic Lecture to Dermatology Residents

Trainee Supervision

Resident

2003 - 2005 Supervisor, (b) (6), University of Utah

2004 - 2006 Supervisor, (b) (6), University of Utah
Medical Student
 1999 - 2001 Supervisor (b) (6), University of Utah
 2001 - 2003 Supervisor, University of Utah
 2002 - 2010 Supervisor, University of Utah
 2004 - 2006 Supervisor, University of Utah
 2009 - 2010 Supervisor, University of Utah
 2010 - Present Supervisor, University of Utah
 2010 - Present Supervisor, University of Utah

Undergraduate

2003 - 2009 Supervisor, (b) (6), University of Utah
 2004 - 2006 Supervisor, University of Utah
 2005 - 2006 Supervisor, University of Utah
 2005 - 2007 Supervisor, University of Utah
 2006 - 2009 Supervisor, University of Utah
 2008 - 2009 Supervisor, University of Utah

Graduate Student Committees

2007 - Present Member, (b) (6), University of Utah, PhD/Doctorate Committee

Educational Lectures

Continuing Education

CE Courses Taught

2004 - Present Structure & Function of the Skin-Nails and Pachyonychia Congenita, American Academy of Dermatology
 2004 - 2007 To Test or Not to Test: p16 Genetic Testing in Familial Melanoma, American Academy of Dermatology
 2008 - Present Cutaneous Cancer Syndromes, American Academy of Dermatology

Education Administration

Other Educational Activities

PEER-REVIEWED JOURNAL ARTICLES

1. Gonzales FR, **Leachman S**, Norgard MV, Radolf JD, McCracken GH Jr, Evans C, Hansen EJ. (1987). Cloning and expression in Escherichia coli of the gene encoding the heat-modifiable major outer membrane protein of Haemophilus influenzae type b. *Infect Immun*, 55(12), 2993-3000.
2. **Leachman SA**, Gallagher PJ, Herring BP, McPhaul MJ, Stull JT. (1992). Biochemical properties of chimeric skeletal and smooth muscle myosin light chain kinases. *J Biol Chem*, 267(7), 4930-8.
3. **Leachman SA**, Insogna KL, Katz L, Ellison A, Milstone LM. (1999). Bone densities in patients receiving isotretinoin for cystic acne. *Arch Dermatol*, 135(8), 961-5.
4. **Leachman SA**, Tigelaar RE, Shlyankevich M, Slade MD, Irwin M, Chang E, Wu TC, Xiao W, Pazhani S, Zelterman D, Brandsma JL. (2000). Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus--rabbit model. *J Virol*, 74(18), 8700-8.
5. Florell SR, Coffin CM, Holden JA, Zimmermann JW, Gerwels JW, Summers BK, Jones DA, **Leachman SA**. (2001). Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol. *Mod Pathol*, 14(2), 116-28.
6. Agarwal-Antal N, Zimmermann J, Scholz T, Noyes RD, **Leachman SA**. (2002). A giant verruciform xanthoma. *J Cutan Pathol*, 29(2), 119-24.
7. **Leachman SA**, Shlyankevich M, Slade MD, Levine D, Sundaram RK, Xiao W, Bryan M, Zelterman D, Tiegelaar RE, Brandsma JL. (2002). Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. *J Virol*, 76(15), 7616-24.
8. Hull C, Alexander A, **Leachman SA**. (2003). Pharmacogenetic candidate genes for melanoma.

Pharmacogenomics, 4(6), 753-765.

9. Florell SR, Boucher KM, **Leachman SA**, Azmi F, Harris RM, Malone JC, Martignoni G, Bowen GM, Gerwels JW, Hood AF. (2003). Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study. *Arch Dermatol*, 139(5), 595-604.
10. **Leachman S**. (2003). Multiple human papillomavirus DNA identified in verruciform xanthoma by nested polymerase chain reaction with degenerate consensus primers. *J Cutan Pathol*, 30(5), 347.
11. Parker JF, Florell SR, Alexander A, DiSario JA, Shami PJ, **Leachman SA**. (2003). Pancreatic carcinoma surveillance in patients with familial melanoma. *Arch Dermatol*, 139(8), 1019-25.
12. Florell SR, Schmidt SJ, Porter-Gill P, Albertine KH, Murphy KJ, McKinney CB, Boucher KM, Grossman D, Biddle DL, Clayton F, Layfield LJ, **Leachman SA**. (2003). Novel application of a fibrin cell block method to evaluate melanocytic cell populations. *Pigment Cell Res*, 16(6), 662-9.
13. Pond CD, **Leachman SA**, Warters RL. (2004). Accumulation, activation and interindividual variation of the epidermal TP53 protein in response to ionizing radiation in organ cultured human skin. *Radiat Res*, 161(6), 739-45.
14. Herron MD, Vanderhooft SL, Smock K, Zhou H, **Leachman SA**, Coffin C. (2004). Proliferative nodules in congenital melanocytic nevi: a clinicopathologic and immunohistochemical analysis. *Am J Surg Pathol*, 28(8), 1017-25.
15. Florell SR, Meyer LJ, Boucher KM, Porter-Gill PA, Hart M, Erickson J, Cannon-Albright LA, Pershing LK, Harris RM, Samlowski WE, Zone JJ, **Leachman SA**. (2004). Longitudinal assessment of the nevus phenotype in a melanoma kindred. *J Invest Dermatol*, 123(3), 576-82.
16. Call TR, Boucher KM, Whiting BL, Hart M, Newman K, Kinney AY, Bowen GM, Zone JJ, Branson D, **Leachman SA**. (2004). Motivating factors for attendance of skin cancer screenings. *J Am Acad Dermatol*, 51(4), 642-4.
17. **Leachman SA**, McLean WHI, Schwartz JN, Schwartz ME. (2005). Preface: Pachyonychia congenita Symposium Proceedings. *J Investig Dermatol Symp Proc*, 10(1), 1-2.
18. Smith FJD, Cassidy AJ, Stewart A, Liao H, Hamill KJ, Wood P, Joval I, van Steensel MAM, Bjorck EJ, Callif-Daley F, Pals G, Collins P, **Leachman SA**, Munro CS, McLean WHI. (2005). The genetic basis of pachyonychia congenita. *J Investig Dermatol Symp Proc*, 10(1), 21-30.
19. Warters RL, Adamson PJ, Pond CD, **Leachman SA**. (2005). Melanoma cells express elevated levels of phosphorylated histone H2AX foci. *J Invest Dermatol*, 124(4), 807-17.
20. Samlowski WE, **Leachman SA**, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR. (2005). Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. *J Clin Oncol*, 23(17), 3897-905.
21. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA, Zone JJ, Samlowski WE, **Leachman SA**. (2005). Population-based analysis of prognostic factors and survival in familial melanoma. *J Clin Oncol*, 23(28), 7168-77.
22. Lewis TB, Robison JE, Bastien R, Milash B, Boucher K, Samlowski WE, **Leachman SA**, Dirk Noyes R, Wittwer CT, Perreard L, Bernard PS. (2005). Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. *Cancer*, 104(8), 1678-86.
23. Wakamatsu K, Kavanagh R, Kadakara AL, Terzieva S, Sturm RA, **Leachman SA**, Abdel-Malek Z, Ito S. (2006). Diversity of pigmentation in cultured human melanocytes is due to differences in the type as well as quantity of melanin. *Pigment Cell Res*, 19, 154-162.
24. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, **Leachman SA**. (2006). Population-based prevalence of CDKN2A mutations in Utah melanoma families. *J Invest Dermatol*, 126(3), 660-6.
25. Liu T, Biddle D, Hanks AN, Brouha B, Yan H, Lee RM, **Leachman SA**, Grossman D. (2006). Activation of dual apoptotic pathways in human melanocytes and protection by survivin. *J Invest Dermatol*, 126(10), 2247-56.
26. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, **Leachman SA**, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Jakobson E. (2006). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. *Cancer Res*, 66(20), 9818-28.
27. Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, **Leachman SA**, Lee RM, Grossman D. (2006). Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist.

- Oncogene*, 25(52), 6968-74.
28. Pho LN, **Leachman SA**. (2007). Genetic Testing for Familial Melanoma: Is It Right for You? *Skin Cancer Foundation Journal*, 25, 23.
 29. Cotter MA, Thomas J, Cassidy P, Robinette K, Jenkins N, Florell SR, **Leachman SA**, Samlowski WE, Grossman D. (2007). N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of UV-induced melanoma in mice. *Clin Cancer Res*, 13, 5952-5958.
 30. Larson AA, **Leachman SA**, Eliason MJ, Cannon-Albright LA. (2007). Population-based assessment of non-melanoma cancer risk in relatives of cutaneous melanoma probands. *J Invest Dermatol*, 127(1), 183-8.
 31. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, **Leachman SA**, MacKie RM, Magnusson V, Mann GJ, Bishop JN, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. (2007). Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. *J Med Genet*, 44(2), 99-106.
 32. Majer M, Jensen RL, Shrieve DC, Watson GA, Wang M, **Leachman SA**, Boucher KM, Samlowski WE. (2007). Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. *Cancer*, 110(6), 1329-37.
 33. Eliason MJ, Hansen CB, Hart M, Porter-Gill P, Chen W, Sturm RA, Bowen G, Florell SR, Harris RM, Cannon-Albright LA, Swinyer L, **Leachman SA**. (2007). Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation. *Arch Dermatol*, 143(11), 1409-12.
 34. Warters RL, Williams DL, Zhuplatov SB, Pond CD, **Leachman SA**. (2007). Protein phosphorylation in irradiated human melanoma cells. *Radiat Res*, 168(5), 535-44.
 35. Liao H, Sayers JM, Wilson NJ, Irvine AD, Mellerio JE, Baselga E, Bayliss SJ, Uliana V, Fimiani M, Lane EB, McLean WH, **Leachman SA**, Smith FJ. (2007). A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita. *J Dermatol Sci*, 48(3), 199-205.
 36. Seltzer MH, **Leachman SA**. (2008). Breast cancer and melanoma in the same pedigree. *Dermatol Online J*, 14(11), 1.
 37. Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, **Leachman SA**. (2008). Increased Melanocytic Nevi and Nevus Density in a G-34T CDKN2A/p16 Melanoma-prone Pedigree. *J Invest Dermatol*, 128(8), 2122-2125.
 38. Oh Adib C, Jones B, Liao H, Smith FJ, Solomon R, Egan CA, **Leachman SA**. (2008). Recurrent Mutation in Keratin 17 in a Large Family with Pachyonychia Congenita Type 2. *Arch Dermatol Res*, 300(5), 211-214.
 39. Pershing LK, Tirmuala VP, Nelson JL, Corlett JL, Lin A, Meyer LJ, **Leachman SA**. (2008). Reflectance Spectrophotometer: The Dermatologist's Sphygmomanometer for Skin Phototyping? *J Invest Dermatol*, 128(7), 1633-1640.
 40. Kohlmann W, Dunn K, **Leachman SA**. (2008). Role of Genetic Testing in Hereditary Melanoma. *Expert Rev Dermatol*, 3(6), 639-643.
 41. **Leachman SA**, Hickerson RP, Hull PR, Smith FJD, Milstone LM, Lane EB, Bale SJ, Roop DR, McLean WHI, Kaspar RL. (2008). Therapeutic siRNAs for Dominant Genetic Skin Diseases Including Pachyonychia Congenita. *J Dermatol Sci*, 51(3), 151-157.
 42. Hickerson RP, Smith FJ, Reeves RE, Contag CH, Leake D, **Leachman SA**, Milstone LM, McLean WH, Kaspar RL. (2008). Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. *J Invest Dermatol*, 128(3), 594-605.
 43. Aspinwall LG, Leaf SL, Dola ER, Kohlmann W, **Leachman SA**. (2008). CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. *Cancer Epidemiol Biomarkers Prev*, 17(6), 1510-9.
 44. Pershing LK, Tirumala VP, Nelson JL, Corlett JL, Lin AG, Meyer LJ, **Leachman SA**. (2008). Reflectance spectrophotometer: the dermatologists' sphygmomanometer for skin phototyping? *J Invest Dermatol*, 128(7), 1633-40.
 45. Florell SR, Smoller BR, Boucher KM, Grossman D, Harris RM, Bowen GM, **Leachman SA**. (2008). Sampling of melanocytic nevi for research purposes: a prospective, pilot study to determine effect on diagnosis. *J Am Acad Dermatol*, 59(5), 814-21.

46. Aspinwall LG, Leaf SL, Kohlmann W, Dola ER, **Leachman SA**. (2009). Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. *J Am Acad Dermatol*, 60(5), 745-57.
47. Bruno W, Ghiorzo P, Battistuzzi L, Ascierto PA, Barile M, Gargiulo S, Gensini F, Gliori S, Guida M, Lombardo M, Manoukian S, Menin C, Nasti S, Origone P, Pasini B, Pastorino L, Peissel B, Pizzichetta MA, Queirolo P, Rodolfo M, Romanini A, Scaini MC, Testori A, Tibiletti MG, Turchetti D, **Leachman SA**, Bianchi Scarra G. (2009). Clinical genetic testing for familial melanoma in Italy: A cooperative study. *J Am Acad Dermatol*, 61(5), 775-82.
48. Hickerson RP, Leake D, Pho LN, **Leachman SA**, Kaspar RL. (2009). Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. *J Dermatol Sci*, 56(2), 82-8.
49. Wilson NJ, Messenger AG, **Leachman SA**, O'Toole EA, Lane EB, McLean WH, Smith FJ. (2010). Keratin K6c mutations cause focal palmoplantar keratoderma. *J Invest Dermatol*, 130(2), 425-9.
50. Warters RL, Cassidy PB, Sunseri JA, Parsawar K, Zhuplatov SB, Kramer GF, **Leachman SA**. (2010). The nuclear matrix shell proteome of human epidermis. *J Dermatol Sci*, 58(2), 113-22.
51. Branstrom R, Kasparian NA, Chang YM, Affleck P, Tibben A, Aspinwall LG, Azizi E, Baron-Epel O, Battistuzzi L, Bergman W, Bruno W, Chan M, Cuellar F, Debniak T, Pjanova D, Ertmanski S, Figl A, Gonzalez M, Hayward NK, Hocevar M, Kanetsky PA, **Leachman SA**, Heisele O, Palmer J, Peric B, Puig S, Schadendorf D, Gruis NA, Newton-Bishop J, Brandberg Y. (2010). Predictors of sun protection behaviors and severe sunburn in an international online study. *Cancer Epidemiol Biomarkers Prev*, 19(9), 2199-210.
52. Jenkins NC, Liu T, Cassidy P, **Leachman SA**, Boucher KM, Goodson AG, Samadashwily G, Grossman D. (2010). The p16(INK4A) tumor suppressor regulates cellular oxidative stress. *Oncogene*. (Epub ahead of print).

NON PEER-REVIEWED JOURNAL ARTICLES

1. **Leachman SA**, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL. (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. *Mol Ther*, 18(2), 442-6.
2. Pho LN, **Leachman SA**. (2010). Genetics of pigmentation and melanoma predisposition. *Giornale Italiano di Dermatologia e Venereologia*, 145(1), 37-45.
3. Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob J-J, Kashani-Sabet M, Kirkwood JM, **Leachman SA**, Messina J, O'Day S, Ribas A, Sondak V. (2010). Meeting Report from the Third Global Workshop on Melanoma. *Pigment Cell Melanoma Res*, 23, e1-e7.

REVIEW ARTICLES

1. Kamm KE, **Leachman SA**, Michnoff CH, Nunnally MH, Persechini A, Richardson AL, Stull JT. (1987). Myosin light chain kinases and kinetics of myosin phosphorylation in smooth muscle cells. [Review]. *Prog Clin Biol Res*, 245, 183-93.
2. Stull JT, Bowman BF, Gallagher PJ, Herring BP, Hsu LC, Kamm KE, Kubota Y, **Leachman SA**, Sweeney HL, Tansey MG. (1990). Myosin phosphorylation in smooth and skeletal muscles: regulation and function. [Review]. *Prog Clin Biol Res*, 327, 107-26.
3. Alexander A, Samlowski WE, Grossman D, Bruggers CS, Harris RM, Zone JJ, Noyes RD, Bowen GM, **Leachman SA**. (2003). Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. [Review]. *J Clin Oncol*, 21(11), 2179-86.
4. Hansen CB, Wadge LM, Lowstuter K, Boucher K, **Leachman SA**. (2004). Clinical germline genetic testing for melanoma. [Review]. *Lancet Oncol*, 5(5), 314-9.
5. **Leachman SA**, Kaspar RL, Fleckman P, Florell SR, Smith FJ, McLean WH, Lunny DP, Milstone LM, van Steensel MA, Munro CS, O'Toole EA, Celebi JT, Kansky A, Lane EB. (2005). Clinical and pathological features of pachyonychia congenita. [Review]. *J Invest Dermatol Symp Proc*, 10(1), 3-17.
6. Smith FJ, Liao H, Cassidy AJ, Stewart A, Hamill KJ, Wood P, Joval I, van Steensel MA, Bjorck E, Callif-Daley F, Pals G, Collins P, **Leachman SA**, Munro CS, McLean WH. (2005). The genetic basis of pachyonychia congenita. [Review]. *J Invest Dermatol Symp Proc*, 10(1), 21-30.
7. Milstone LM, Fleckman P, **Leachman SA**, Leigh IM, Paller AS, van Steensel MA, Swartling C. (2005). Treatment of pachyonychia congenita. [Review]. *J Invest Dermatol Symp Proc*, 10(1), 18-20.
8. Pho L, Grossman D, **Leachman SA**. (2006). Melanoma genetics: a review of genetic factors and clinical phenotypes

- in familial melanoma. [Review]. *Curr Opin Oncol*, 18(2), 173-9.
9. **Leachman SA**, Jackson R, Eliason MJ, Larson AA, Bologna JL. (2007). Management of melanoma during pregnancy. [Review]. *Dermatol Nurs*, 19(2), 145-52, 161.
 10. **Leachman SA**, Hickerson RP, Hull PR, Smith FJ, Milstone LM, Lane EB, Bale SJ, Roop DR, McLean WH, Kaspar RL. (2008). Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. [Review]. *J Dermatol Sci*, 51(3), 151-7.
 11. **Leachman SA**, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarra G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H. (2009). Selection criteria for genetic assessment of patients with familial melanoma. [Review]. *J Am Acad Dermatol*, 61(4), 677.e1-14.

BOOKS

BOOK CHAPTERS

1. Kamm KE, **Leachman SA**, Michnoff CH, Nunnally MH, Persechini A, Richardson AL, Stull JT. (1987). Myosin light chain kinases and kinetics of myosin phosphorylation in smooth muscle cells. In Siegman MJ; Somlyo AP; Stephens NL (Ed.), *Proceedings of the IUPS Conference on Contraction of Smooth Muscle*. New York: A Liss Inc.
2. Stull JT, Bowman BF, Gallagher PJ, Herring BP, Hsu LC, Kamm KE, Kubota Y, **Leachman SA**, Sweeney HL, Tansey MG. (1989). Myosin phosphorylation in smooth and skeletal muscles: regulation and function. In Sperelakas N; Wood JD (Ed.), *Frontiers in Smooth Muscle Research*. New York: Wiley-Liss.
3. **Leachman SA**, Brandsma JL. (1998). Nucleic Acid Vaccines for Immunization Against Papillomavirus Induced Lesions. In *Human Papillomavirus Vaccines*. Ed. by R Tindle, Landes Bioscience, Austin, TX.
4. Hanson N, **Leachman S**. (2001). Safety issues in isotretinoin therapy. In Diane M. Thiboutot (Ed.), *Seminars in Cutaneous Medicine and Surgery* (20.3). London: Blackwell Science.
5. **Leachman SA**. (2001). Surgical Therapies, part III: Melanocyte Transplants. In *Dermatologic Therapy*. Ed. by Jean Bologna, Blackwell Science (14, pp. 20-28).
6. **Leachman SA**, Lowstuter K, Wadge LM. (2004). Genetic Testing for Melanoma. In Darrel S. Rigel (Ed.), *Cancer of the Skin*. Philadelphia: Elsevier Saunders.
7. **Leachman SA**, Reed BR. (2006). The use of dermatologic drugs in pregnancy and lactation. In *Dermatologic Clinics*. Philadelphia: Elsevier Saunders.
8. Choueiri TK, Olencki T, Samlowski WE, Florell SR, **Leachman SA**, Majer M, Vidimos A. (2006). Unusual Cutaneous Malignancies. In *Textbook of Uncommon Cancer* (Third Edition). Wiley & Sons, Ltd.
9. Aspinwall LG, Leaf SL, **Leachman SA**. (2009). Meaning and agency in the context of genetic testing for familial cancer. In PTP Wong (Ed.), *The Human Quest for Meaning* (2nd Edition). Hillsdale, NJ: Lawrence Erlbaum.

CONFERENCE PROCEEDINGS

OTHER (Commentary/Letters/Editorials/Case Reports/Video/Film)

Case Reports

1. Alexander A, Harris RM, Grossman D, Bruggers CS, **Leachman SA**. (2004). Vulvar melanoma: diffuse melanosis and metastasis to the placenta. *J Am Acad Dermatol*, 50(2), 293-8.

Letters

1. Florell SR, Boucher KM, Holden JA, Meyer LJ, Samlowski WE, Cannon-Albright LA, Zone JJ, **Leachman SA**. (2002). Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and non-carriers [Letter to the editor]. *J Invest Dermatol*, 118(2), 386-7.
2. Milstone LM, Insogna KL, **Leachman SA**. (2005). Isotretinoin does have an adverse effect on bone mineral density [Letter to the editor]. *J Am Acad Dermatol*, 53(1), 181; author reply 182-3.
3. Florell SR, Meyer LJ, Boucher KM, Hart M, Cannon-Albright LA, Harris RM, Grossman D, Samlowski WE, Zone JJ, Brinton JP, **Leachman SA**. (2005). Nevus distribution in a Utah melanoma kindred with a temperature-sensitive

- CDKN2A mutation [Letter to the editor]. *J Invest Dermatol*, 125(6), 1310-2.
4. Cotter MA, Florell SR, **Leachman SA**, Grossman D. (2007). Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo [Letter to the editor]. *J Invest Dermatol*, 127(10), 2469-71.
 5. Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, **Leachman SA**. (2008). Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree [Letter to the editor]. *J Invest Dermatol*, 128(8), 2122-5.

Patents

(b) (4)

PENDING PUBLICATIONS

Journal Articles

(b) (4)

RECENTLY PUBLISHED ABSTRACTS (Last 3 Years)

UNPUBLISHED POSTER PRESENTATIONS

1. **Leachman SA**, Brownstein DG, Chang E, Xiao W, Brandsma JL. (1997). *Recruitment of MHC Class II-Positive Lymphocytes into Skin by Intracutaneous Inoculation of DNA Encoding GM-CSF*.
2. **Leachman SA**, Insogna KL, Katz L, Ellison A, Milstone LM. (1999). *Effects of Isotretinoin on Bone Density and Calcium Metabolism, Chicago, IL*.
3. **Leachman SA**, DiMaio D, Zimmermann JW, Goodwin EC. (2001). *Transcriptional Alterations Induced by Papillomavirus E2 Protein, Newport, RI*.
4. Florell SR, Grossman D, Meyer LJ, **Leachman SA**. (2002). *Apoptosis Index of Nevi in Utah Kindred Members With and Without CDKN2A Mutations, Los Angeles, CA*.
5. Florell SR, Porter-Gill PA, Schmidt S, **Leachman SA**. (2002). *Fibrin Cell Plug method to Confirm Nevomelanocytic Cell Lineage, Amsterdam*.
6. Florell SR, Boucher KM, **Leachman SA**, Farrukh A, Harris RM, Malone J. (2002). *Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study*. Poster session presented at International Academy of pathology Meeting, Chicago, IL.
7. **Leachman SA**, Hansen C, Wadge L, Porter-Gill PA, Florell SR, Swinyer L. (2002). *Multiple Primary Melanomas in*

- a CDKN2A Mutation Carrier Exposed to Ionizing Radiation.*
8. Pond C. (2003). *Accumulation and Activation of the p53 Protein in Human Skin in Response to Ionizing Radiation.*
 9. Pond CD, **Leachman SA**, Warters RL. (2003). *Accumulation and activation of the p53 protein in human skin in response to ionizing radiation.* Poster session presented at American Association for Cancer Research, Washington, D.C.
 10. **Leachman SA**, Porter-Gill PA, Erickson H, Schmidt S, Judd J, Florell SA. (2003). *Cyclin-dependent Kinase 2A Function in the Familial Melanoma Syndrome.*
 11. Warters RL, Pond CD, Adamson PJ, **Leachman SA**. (2003). *Ionizing Radiation-Induced DNA Damage Response in Cultured Human Skin Cells.*
 12. Florell SR, Meyer LJ, Boucher KM, Porter-Gill P, Erickson H, Cannon-Albright LA, Harris R, Samlowski W, Zone JJ, **Leachman SA**. (2003). *Phenotypic Observations of a Utah Melanoma Kindred: Fifteen Years Later.*
 13. Pond CD, **Leachman SA**, Warters RL. (2003). *Post-translational modifications of DNA damage response proteins as a measure of cellular response to low doses of ionizing radiation.* Poster session presented at Contractors Meeting, United States Dept of Energy, Washington, D.C.
 14. Florell SR, Porter-Gill PA, Schmidt SA, Erickson H, **Leachman SA**. (2003). *Rapid Quantitation of Immunostained Cultured Cells in a Formalin-fixed, Paraffin-embedded Fibrin Cell Block.*
 15. Porter-Gill :A, Erickson HM, Eller MS, Florell SR, Gilchrest BA, **Leachman SA**. (2004). *p16 mutational status influences responses to T-oligo-simulated DNA damage.* Poster session presented at The Society for Investigative Dermatology, Providence, RI.
 16. Warters RL, Adamson P, Pond CD, **Leachman SA**. (2004). *Micronucleus induction by ionizing radiation in primary skin cells.* Poster session presented at Radiation Research Meeting, St. Louis, MO.
 17. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, **Leachman SA**. (2004). *Prevalence of CDKN2A mutations in familial melanoma.* Poster session presented at American Society of Human Genetics, Toronto, Ontario, Canada.
 18. Liao H, Stewart A, **Leachman SA**, McLean W, Smith FJ. (2005). *Molecular genetic analysis of 31 pachyonychia congenita families.* Poster session presented at The Society for Investigative Dermatology, St. Louis, MO.
 19. Warters RL, Pond CD, Williams DL, **Leachman SA**. (2005). *Protein phosphorylation in irradiated human cells.* Poster session presented at AACR Meeting, Anaheim, CA.
 20. Warters RL, Williams DL, Pond CD, **Leachman SA**. (2005). *Protein phosphorylation in irradiated human cells.* Poster session presented at Radiation Research Society Annual Meeting, Denver, CO.
 21. Ridky TW, Yang E, **Leachman SA**, Khavari P. (2005). *The structural integrity of individual keratin filament networks is dispensable for epidermal tumorigenesis.* Poster session presented at The Society for Investigative Dermatology, St. Louis, MO.
 22. Eliason MJ, Milstone LM, **Leachman SA**. (2006). *A comparison of patient experience with published treatments of pachyonychia congenital.* Poster session presented at The Society for Investigative Dermatology, Philadelphia, PA.
 23. Warters RL, Zhuplatov SB, Williams DL, Pond CD, **Leachman SA**. (2006). *Assessment of p53 Protein Expression in Human Skin Models.* Poster session presented at 45th Annual Meeting of the American Society for Cell Biology, San Diego, CA.
 24. Warters RL, Zhuplatov SB, Williams DL, Pond CD, **Leachman SA**. (2006). *Assessment of the p53 response of keratinocytes in culture and in intact human skin.* Poster session presented at DOE Low Dose Radiation Research Program: Workshop VI, Washington, D.C.
 25. Smith FJD, Hickerson RP, Liao H, Sayers J, **Leachman SA**, Leake D, Kaspar RL, McLean WHI. (2006). *Development of Therapeutic siRNA's for Treatment of Pachyonychia Congenita.* Poster session presented at ESDR Meeting, Paris, France.
 26. Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, **Leachman SA**, Lee R, Grossman D. (2006). *Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist.* Poster session presented at The Society for Investigative Dermatology, Philadelphia, PA.
 27. **Leachman SA**, Eliason MJ, Benson N, Malmstrom S, McLean WH, Milstone LM, Kaspar R, Calebi JT, Smith FJ. (2006). *Non-invasive analysis of keratin expression for pachyonychia congenita clinical trials.* Poster session presented at The Society for Investigative Dermatology, Philadelphia, PA.
 28. **Leachman SA**, Boucher K, Cassidy P, Pimentel R, Mineau G, Cannon-Albright L, Florell S, Grossman D, Andtbacka R, Bowen G. (2007). *A Preliminary Study of the Design and Feasibility of Melanoma Prevention*

- Trials*. Poster session presented at International Melanoma Congress, New York, NY.
29. Pho L, Hicherson R, Kaspar R, Boucher K, McLean WH, Smith F, **Leachman SA**. (2007). *Development and validation of an allele-specific quantitative RT-PCR assay for pachyonychia congenita*. Poster session presented at The Society for Investigative Dermatology, Long Beach, CA.
 30. Pho L, Florell S, Harris R, Bowen A, Munro C, Liao H, Smith F, **Leachman SA**. (2007). *Hair abnormalities are rare in pachyonychia congenita*. Poster session presented at The Society for Investigative Dermatology, Long Beach, CA.
 31. Florell SR, Meyer LJ, Boucher KM, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, **Leachman SA**. (2007). *Increased melanocytic nevi and nevus density in a G-34T CDKN2A melanoma-prone kindred*. Poster session presented at The Society for Investigative Dermatology, Long Beach, CA.
 32. Abdel-Malek ZA, Kadarko AL, Kavanagh R, Swope V, **Leachman SA**. (2007). *Molecular Mechanisms for Increased Melanoma Susceptibility by loss of function of MC1R*. Poster session presented at Pan American Society for Pigment Cell Research (PASPCR), Chicago, IL.
 33. Cai Q, Cassidy P, Manga P, Florell SR, Cannon-Albright L, **Leachman SA**. (2007). *Molecular and phenotypic characterization of a new OCA2 mutation in humans*. Poster session presented at Pan American Society for Pigment Cell Research (PASPCR), Chicago, IL.
 34. Pho P, Liao H, Smith F, Konecki D, Bale S, McLean I, Cohen B, Eliason M, **Leachman SA**. (2007). *Paternal germline mosaicism in pachyonychia congenita*. Poster session presented at The Society for Investigative Dermatology, Long Beach, CA.
 35. Warters RL, Zhuplatov SB, Hoenicke GF, **Leachman SA**, Moos PJ. (2007). *Radiation-induced Stress Response in Human skin*. Poster session presented at International Congress of Radiation Research (ICRR), San Francisco, CA.
 36. Kaspar RL, Hickerson RP, Pho L, **Leachman SA**. (2007). *Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and alters clinical symptoms in an off-label study in pachyonychia congenita patients*. Poster session presented at The Society for Investigative Dermatology, Long Beach, CA.
 37. **Leachman SA**, Hickerson RP, Schwartz ME, Smith FJ, McLean W, Milstone LM, Kaspar RL. (2008). *First-In-Skin siRNA Clinical Trial for Pachyonychia Congenita*. Poster session presented at International Investigative Dermatology, Kyoto, Japan.
 38. Wilson NJ, Messenger AG, **Leachman SA**. (2008). *Keratin K6c mutations cause focal keratoderma*. Poster session presented at International Investigative Dermatology, Kyoto, Japan.
 39. Warters RL, Zhuplatov S, **Leachman SA**. (2008). *The Nuclear Matrix Phosphoproteome of Skin Cells and Their Cancers*. Poster session presented at The American Association of Cancer Research (AACR), San Diego, CA.
 40. Cassidy P, Fain H, Cassidy Jr. JP, Tran S, Moos P, **Leachman SA**. (2008). *The effects of selenium on melanoma cells*. Poster session presented at The American Association of Cancer Research (AACR), San Diego, CA.
 41. Kaspar RL, Garcia M, Hicherson RP, Del Rio M, **Leachman SA**, Leake D, Milstone LM, Larcher F. (2008). *Use of Pachyonychia Congenita Patient-Derived Keratinocytes to 1) Demonstrate the Effectiveness of Therapeutic TD101 siRNA and 2) Generate a Humanized Mouse Disease Model*. Poster session presented at International Investigative Dermatology, Kyoto, Japan.
 42. Hickerson RP, **Leachman SA**, Pho LN, Smith FJ, Leake D, McLean W, Kaspar RL. (2008). *Development of a PCR-based Quantitative Clinical Endpoint to Determine the Effectiveness of siRNA Therapy in a Phase 1b Trial in Pachyonychia Congenita Patients*. Poster session presented at International Investigative Dermatology, Kyoto, Japan.
 43. Abdel-Malek ZA, Kadarko AL, Swope V, Starner R, Supp D, Wakamatsu K, Ito S, Cassidy P, **Leachman SA**. (2009). *Correlation of the MC1R Genotype with the UV Response of Human Melanocytes: Implications on Melanoma Susceptibility*. Poster session presented at 15th PanAmerican Society for Pigment Cell Research Conference, Memphis, TN.
 44. Hickerson RP, **Leachman SA**, Pho LN, Smith FD, McLean W, Leake D, Milstone LM, Kaspar RL. (2009). *Further Pre-clinical Characterization of TD101 - the First siRNA to Enter Clinical Trials for a Skin Disorder*. Poster session presented at The Society of Investigative Dermatology, Montreal, Canada.
 45. Harris K, Florell SR, Papenfuss J, Kohlmann W, bowen GM, **Leachman SA**. (2009). *Multiple Pagetoid Spitz Nevi*. Poster session presented at The Society of Investigative Dermatology, Montreal, Canada.
 46. **Leachman SA**, Hicherson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FD, McLean W, Milstone LM, Kaspar RL. (2009). *Mutation-specific siRNA Resolves Callus in a Pachyonychia Congenita Patient*. Poster session presented at The Society of Investigative

Dermatology, Montreal, Canada.

47. Wilson LH, Gawlick U, Noyes RD, Florell S, Coleman L, Bowen A, Blaser J, Lundell R, Harris R, Bowen GM, **Leachman SA**, Grossman D, Andtbacka RHI. (2009). *Sentinel lymph node biopsy in atypical spitzoid tumors*. Poster session presented at The Society of Surgical Oncology, Phoenix, AZ.

ORAL PRESENTATIONS

Keynote/Plenary Lectures

Meeting Presentations (Not Published Abstracts and Not Unpublished Posters)

International

- 2000 Florell SR, Coffin CM, Holden JA, Zimmermann JW, Gerwels JW, Summers BK, Jones DA, Leachman SA. Preservation of RNA for Functional Genomic Studies: A Multidisciplinary Tumor Bank Protocol.
- 2002 Leachman SA, Hanson NW, Hinshaw J, Amoss MS, Szabo A, Florell SR. CDNA Microarray Expression Profiling of Melanomas from Sinclair Miniature Swine. 18th International Pigment Cell Conference, Amsterdam

National

- 1996 Leachman SA, Schechner J, Scully M, Imaeda S. Mycotic Masquerade: Disseminated Blastomycosis. American Academy of Dermatology Meeting, Washington, D.C.
- 2001 Melanoma Research Foundation Symposium
- 2002 Leachman SA, Astle J, Boucher K, Kerber R, Mineau G, Wiggins C, Tsodikov A. Prognostic Factors and Survival in Familial Melanoma. 63rd Annual Meeting of The Society for Investigative Dermatology, LA
- 2003 Alexander A, Leachman SA, Cannon-Albright LA. Population-based Assessment of Cancer Risk in Relatives of Melanoma Proband, The Society for Investigative Dermatology, Miami, FL
- 2005 Abdel-Malek ZA; Kadekaro A; Hauser J; Terzieva S; Kavanagh R; Leachman SA. Loss of function alleles of the melanocortin 1 receptor gene increases the risk for melanoma by increasing UV-induced oxidative stress and reducing the repair of DNA photo products, St. Louis, MO
- 2005 Florell SR, Meyer LJ, Boucher KM, Hart M, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, Brinton JP, Leachman SA. Does a temperature-sensitive CDKN2A mutation confer temperature-dependent nevus distribution? The Society of Investigative Dermatology, St. Louis, MO
- 2007 Abdel-Malek ZA; Kadekaro AL; Supp D; Swope V; Mosby N; Kavanagh RJ; Koshoffer A; Boissy RE; Leachman SA. Evidence for the Significance of the Melanocortin 1 Receptor in the DNA Damage Response of Human Melanocytes and Melanoma Susceptibility, Chicago, IL
- 2008 SPORE Conference, New Haven, CT, "Population-based analysis of prognostic factors and survival in familial melanoma, data collection, management, what does it take?"
- 2008 American Academy of Dermatology, San Antonio, TX, "Cutaneous Cancer Syndromes"

Local/Regional

- 2002 Pond CD, Leachman SA, Warters RL. Post-translational Modifications of DNA Damage Response Proteins as Measure of Cellular Response to Low Doses of Ionizing Radiation

Invited/Visiting Professor Presentations

International

- 2004 "Prognostic Factors and Survival in Familial Melanoma." Second International Melanoma Research Congress, Phoenix, AZ
- 2004 "Hereditary Melanoma: Management of High Risk Patients," Winter Skin Seminar, Whistler, British Columbia, Canada.
- 2004 "An Ounce of Prevention, Sunscreens, and More," Winter Skin Seminar, Whistler, British Columbia, Canada
- 2005 "Familial Melanoma: A Model for Translational Melanoma Research," University of Maastricht, The Netherlands
- 2005 "Pros & Cons of Genetic Testing," Sixth World Congress on Melanoma, Vancouver, British

- Columbia, Canada.
- 2005 "Update on Utah Melanoma Families," The Melanoma Consortium Meeting, Leiden, The Netherlands
- 2005 "Contemporary Management of the Dysplastic Nevus Syndrome," Second International Symposium on Melanoma and Other Cutaneous Malignancies, New York, NY
- 2006 "What you need to know about Pachyonychia Congenita" Pacyonichia Congenita Patient Support Meeting, Scotland
- 2006 "Population-based Assessment of CDKN2A and Melanoma-Associated Non-Melanoma Cancer Incidence in Utah," Annual GenoMEL Meeting, Genoa, Italy
- 2006 "Hereditary Melanoma," Third International Symposium on Melanoma and Other Cutaneous Malignancies, New York, NY.
- 2007 "Genetic Differences Among Patients Based on Sun Exposure," Fourth International Symposium on Melanoma and Other Cutaneous Malignancies, New York, NY
- 2007 "Etiology, Epidemiology, and Molecular Biology: Implications for Therapeutic Intervention," First Global Workshop on Malignant Melanoma (PER), Puerto Rico
- 2007 "Progress on Pachyonychia Congenita," 1st World Congress on Genodermatology, Maastricht, The Netherlands
- 2008 "How genetic test reporting affects patient screening and adherence to surveillance recommendations," GenoMEL Conference, Paris, France
- 2008 "Should Genetic Testing be Used Clinically?" 5th International Symposium on Melanoma and Other Cutaneous Malignancies, New York, NY
- 2008 "The Missing (Older) Man: How can we reach the people most in need of skin screening?" 2nd Annual World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers Meeting, Clearwater Beach, FL
- 2009 "Genetherapy of Keratin Disorders," Ichthyosis Consensus Conference, Soreze, France
- 2009 "First-in-Skin siRNA Clinical Trial," Keystone Symposia: Therapeutic Modulation of RNA Using Oligonucleotides, Alberta, Canada
- 2009 The Genetic Counseling Package, GenoMEL Melanoma Genetics Consortium Meeting, Ljubljana, Slovenia
- 2009 TD101 Clinical Trial: Intradermal Injection of siRNA, International PC Consortium, Montreal, Quebec, Canada
- 2009 Melanoma genetic counseling and testing improves patient compliance and perceived control, 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers Conference, Berlin, Germany
- 2010 Genetics of Melanoma: Impact on Diagnosis and Therapeutic Decisions, International Hematology/Oncology Forum:
Spotlight on Melanoma, CML and Breast Cancer, Cancun, Mexico

National

- 1996 "On the Border of Vitiliginous Versus Pigmented Skin," Pigment Club, American Academy of Dermatology, Washington, D.C.
- 1999 "Unusual Dermal Melanocytosis", Pigment Club, American Academy of Dermatology, New Orleans, LA
- 2000 "Isotretinoin and Bone Density", American Academy of Dermatology's Academy, Nashville, TN
- 2001 "Papillomavirus: From Verruca Vulgaris to Squamous Cell Carcinoma, Clinical Disease & Its Molecular Basis," American Academy of Dermatology 59th Annual Meeting, Washington, D.C.
- 2001 "Hereditary Melanoma," Yale University School of Medicine, Department of Dermatology Grand Rounds and Noon Lecture Series, New Haven, CT.
- 2001 "Melanocyte Transplantation for the Treatment of Vitiligo," Annual Meeting, American Academy of Dermatology, Anaheim, CA
- 2003 "The Familial Melanoma Research Program in Utah", Invited speaker to Melanoma Consortium, Philadelphia, PA
- 2003 "Is it Time for Genetic Testing for Melanoma?" Invited lecturer at the American Academy of

2003 Dermatology 2003 Meeting, San Francisco, CA
 "Diagnostic Targets for Early Detection of Melanoma", Invited speaker to CHI Conference, Santa Clara, CA

2004 "To Test or Not to Test: p16 Genetic Testing in Familial Melanoma," American Academy of Dermatology, Washington, D.C

2005 "To Test or Not to Test: p16 Genetic Testing in Familial Melanoma," American Academy of Dermatology, New Orleans, LA

2005 "Drugs, Pregnancy, and the Skin," "Melanoma Pregnancy," American Academy of Dermatology, New Orleans, LA

2005 "The Role of Genetic Testing in Melanoma," Twenty-fourth Anniversary Fall Clinical Dermatology Conference, Las Vegas, NV

2006 "To Test or Not to Test: p16 Genetic Testing in Familial Melanoma," American Academy of Dermatology, San Francisco, CA

2006 "Hereditary Melanoma" 13th Annual PASPCR Meeting / The Melanocyte and its Environment. Cincinnati, OH

2007 "Genetic Testing for Melanoma Risk Stratification," Melanoma Care Coalition Regional Symposium, Cincinnati, OH

2007 "Screening for CDKN2A mutations in familial melanoma: national consensus" Melanoma Prevention Working Group (SWOG), Huntington Beach, CA

2007 "To Test or Not to Test: p16 Genetic Testing in Familial Melanoma," American Academy of Dermatology, Washington, DC

2008 "Cutaneous Cancer Syndromes", American Academy of Dermatology, San Antonio, TX

2008 "Nails and Pachyonychia Congenita", American Academy of Dermatology, San Antonio, TX

2008 "Structure and Function of the Skin - Nails and Pachyonychia Congenita", American Academy of Dermatology, San Antonio, TX

2008 "Bench to Bedside: Pachyonychia Congenita Project," 34th Annual Meeting Society of Pediatric Dermatology, Snowbird, UT

2008 "Population-based analysis of prognostic factors and survival in familial melanoma, data collection, management, what does it take?" SPORE Conference, New Haven, CT

2009 "Nails and Pachyonychia", American Academy of Dermatology, San Francisco, CA

2009 "An Ounce of Melanoma Prevention", 9th Annual Oncology Update: Advances and Controversies," Park City, UT

2009 "siRNA Therapeutics for the Treatment of Pachyonychia Congenita," American Academy of Dermatology, San Francisco, CA

2009 "Do I Need to be Genetically Tested for Melanoma?" American Academy of Dermatology, San Francisco, CA

2009 "Population at Risk to Target for Melanoma Genetic Testing," American Academy of Dermatology, San Francisco, CA

2009 Mutation Specific siRNA Resolves Callus in a Pachyonychia Congenita Patient, 69th Annual Society for Investigative Dermatology Meeting, Montreal, Quebec, Canada

2009 Selenium for the Prevention and Treatment of Melanoma, 15th Meeting of PanAmerican Society for Pigment Cell Research, Memphis, TN

2009 Current Understanding of the Genetics of Melanoma, Perspectives in Melanoma XIII, Baltimore, MA

2010 The Role of Gene Mutations in New Therapies, AIM at Melanoma, Pittsburgh, PA

2010 The Future – Clinical Trials and Studies, Society for Investigative Dermatology, Atlanta, GA

2010 Frontiers in Preparing for Clinical Trials, Foundation for Ichthyosis and Related Skin Types, Orlando, FL

2010 Nails and Pachyonychia Congenita, American Academy of Dermatology, Miami Beach, FL

2010 First-in-skin siRNA Therapeutic for Pachyonychia Congenita, Atlanta Dermatological Association Conference, Atlanta GA

2010 Biological Therapies in Pregnancy, American Academy of Dermatology, Miami Beach, FL

2010 Prevention Among High Risk Families, American Academy of Dermatology, Miami Beach, FL

- 2010 Update on Melanoma Genetics, Atlanta Dermatological Association Conference, Atlanta GA
 2010 Overview of Cutaneous Cancer Syndromes, American Society of Clinical Oncology, Chicago, IL
 2010 Hereditary Melanoma: New Developments, 10th Annual Cancer Conference, Canton OH

Local/Regional

- 1998 Leachman SA, Halaban R, Lerner AB. "Melanocyte Transfer for the Treatment of Vitiligo", Intermountain Dermatology Society Meeting, Sun Valley, ID
 1999 "Autologous Melanocyte Transfer for Vitiligo", Westwood Squibb Winter Skin Seminar, Snowbird, UT
 2001 "The Familial Melanoma Research Clinic," Director Series, Huntsman Cancer Institute, Salt Lake City, UT
 2001 "The Familial Melanoma Research Clinic," Melanoma Research Foundation Symposium at HCI, Salt Lake City, UT
 2002 "The Huntsman Cancer Institute Familial Melanoma Research Program", Guest Lecturer at the Arizona Cancer Center, Tucson, AZ
 2002 "Is It Time for Clinical Genetic Testing for Melanoma?" Invited speaker for Myriad Genetics, Salt Lake City, UT
 2002 "Clinical Genetic Testing for Melanoma", Invited speaker at the Utah Dermatologic and Surgical Society Meeting, Zion, UT
 2004 "Let the Sunshine in, But Protect Your Skin!" Speaking of Women's Health, local meeting of national conference, Salt Lake City, UT.
 2004 "The Melanoma Program at Huntsman Cancer Institute," Arizona Cancer Center, University of Arizona, Tucson, AZ
 2005 "Skin Flix: Genetic Traits and Skin Cancer," University of Utah for the Genetic Science Learning Center, Natural History Museum, Salt Lake City, UT
 2005 "Genetic Testing for Hereditary Melanoma," Utah Cancer Registry, LDS Hospital, Salt Lake City, UT.
 2006 "Pros & Cons of Melanoma Genetic Testing," Myriad Genetics, Inc., University Park Marriott Hotel, Salt Lake City, UT
 2006 "Sun Safety: Protecting our Children's Skin" Davis School District Fall Workshop, Bountiful, UT
 2006 "Hereditary Melanoma: Where Do We Stand?" St. Joseph Hospital Regional Cancer Center Ninth Annual Melanoma Symposium, The Balboa Bay Club & Resort, Newport Beach, CA.
 2008 "Genetic Testing for Melanoma Risk Stratification", Pacific Dermatology Association Annual Meeting, San Francisco, CA
 2008 "Discover the 'Super Powers' of Smart Skincare", Speaking of Women's Health, Salt Lake City, UT
 2010 Update on Hereditary Melanoma, Current Trends in the Genetics of Melanoma and Clinical Implications, Tucson, AZ
 2010 Melanoma in Pregnancy, Current Trends in the Genetics of Melanoma and Clinical Implications, Tucson, AZ

Grand Rounds Presentations

- 1998 - Present Department of Dermatology Grand Rounds
 2001 Department of Dermatology Grand Rounds and Noon Lecture Series, New Haven, CT, "Hereditary Melanoma"
 2008 University of Massachusetts, Worcester, MA Grand Rounds
 2009 University of California/Irvine, Irvine, CA Grand Rounds, "siRNA Therapeutics for Pachyonychia Congenita"
 2009 University of New Mexico, Albuquerque, NM Grand Rounds, "Utilizing Utah Population Resources to Investigate Melanoma"

Industrial Presentations

Outreach Presentations

OTHER SCHOLARLY ACTIVITY